Genpact Limited SEC Filings

Anil Nanduru, Senior Vice President at Genpact Limited (G), reported two open-market sales of company common shares on Aug 21–22, 2025. He sold 18,218 shares on 08/21/2025 at $44.50 per share and 9,744 shares on 08/22/2025 at $45.50 per share, reducing his beneficial ownership to 89,846 common shares after the transactions. The filing notes that his total holdings include 237 shares received via dividend reinvestment since his prior Form 4. The Form 4 is signed by an attorney-in-fact for the reporting person.

Genpact Limited insider Form 4: Senior Vice President Riju Vashisht reported two open-market sales of Genpact (G) common shares on 08/22/2025. The first sale disposed of 17,608 shares at a weighted average price of $45.61, leaving 130,201 shares beneficially owned. The second sale disposed of 7,931 shares at a weighted average price of $45.57, leaving 122,270 shares beneficially owned. The combined number of shares sold was 25,539. The form notes the price ranges for the sales and discloses the reporting person holds 4,154 shares via the Employee Stock Purchase Plan, including 160 shares acquired since the prior Form 4. The filing was signed by an attorney-in-fact on 08/25/2025.

Form 144 notice indicates a proposed sale of 9,744 common shares through Morgan Stanley Smith Barney on 08/22/2025 with an aggregate market value of $443,352.00. The shares were acquired as restricted stock from the issuer on 01/10/2025 and paid for on that date. The filer disclosed two prior sales on 08/21/2025 totaling 18,218 shares for gross proceeds of $810,701.00 (listed as $505,119.50 and $305,581.50). The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.

Form 144 notice for Genpact Limited (symbol: G) discloses a proposed sale of 25,539 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $1,164,468.47 and approximately 174,270,076 shares outstanding. The shares were acquired as performance shares: 17,608 on 01/10/2022 and 7,931 on 01/10/2023. No securities were reported sold by the selling person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information and follows the Rule 144 disclosure process.

Genpact Limited (G) filing a Form 144 notifies the proposed sale of 18,218 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $810,701.00. The shares were granted as performance shares and were acquired in two tranches: 11,351 on 01/10/2022 and 6,867 on 01/10/2023. The filing lists 174,270,076 shares outstanding for the class and indicates no reported sales by the seller in the past three months. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information.

Carol Lindstrom, a director of Genpact Limited (ticker G), reported a sale of 2,326 common shares on 08/12/2025 at $43.17 per share. After the disposition she beneficially owned 21,185 shares directly. The filing is limited to a single non-derivative sale and shows no option or derivative activity.

Genpact director Thimaya K. Subaiya received an award of unvested restricted share units (RSUs) under the Genpact Limited 2017 Omnibus Incentive Compensation Plan reported on 08/12/2025. Each RSU converts one-for-one into a common share and the filing shows the reporting person as beneficially owning 2,020 shares following the award. The RSUs fully vest on December 31, 2025 subject to continued service and will be settled in common shares on December 31, 2026. The Form 4 indicates a compensatory grant (price shown as $0) and was filed by a single reporting person.

Genpact Limited submitted a Form 144 notice for the proposed sale of 2,326 common shares, with an aggregate market value of $100,413.42. The shares represent a small fraction of the issuer's outstanding common stock (174,270,076 shares outstanding) and were acquired as restricted stock on 12/31/2019. The broker listed is Morgan Stanley Smith Barney LLC and the securities are designated for sale on the NYSE with an approximate sale date of 08/12/2025. The form indicates no securities sold in the past three months and includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.

Genpact reported continued top-line and profit growth for the quarter ended June 30, 2025. Net revenue rose to $1.254 billion from $1.176 billion a year earlier, while net income increased to $133 million from $122 million, producing diluted EPS of $0.75 versus $0.67. Gross profit and operating income also increased, reflecting higher revenues partially offset by higher SG&A.

The balance sheet expanded: total assets grew to $5.308 billion and shareholders' equity to $2.587 billion. Cash and equivalents were $663 million. The company completed the acquisition of XponentL for total consideration of $159.8 million (including a $77.5 million contingent earn-out recognized at fair value), recording $111.9 million of goodwill and customer/marketing intangibles. Short-term borrowings and the current portion of long-term debt rose (current portion $375.7 million), and the allowance for credit losses on receivables increased to $26.8 million.